RECRUITING

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Description

The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.

Conditions

Obesity
Talk to us

Related Conditions:

Obesity

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.

A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Knoxville

MBX Biosciences Investigational Site, Knoxville, Tennessee, United States, 37920

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age of \>18 to ≤65 years at the time of signing the informed consent.
  • * Has a BMI of ≥30 to \<40 kg/m2 at screening and baseline.
  • * Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.
  • * History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
  • * History of currently active pancreatitis, type I and type II diabetes.
  • * Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.
  • * A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

MBX Biosciences,

Study Record Dates

2026-05-30